Reviva Pharmaceuticals Holdings stock analysis
Want to see RVPH full AI Analyst Report?
Reviva Pharmaceuticals Holdings (RVPH) Stock Price & Analysis
RVPH Stock Chart & Stats
- Day’s Range
- $0.28 - $0.37
- 52-Week Range
- $0.26 - $15.42
- Previous Close
- $0.28
- Volume
- N/A
- Average Volume (3M)
- 32.87K
- Market Cap
- $3.93M
- Enterprise Value
- -$11.21M
- Total Cash (Recent Filing)
- $17.46T
- Total Debt (Recent Filing)
- $44.39B
- Price to Earnings (P/E)
- ―
- Beta
- 1.70
- Next Earnings
- Apr 05, 2027 (Est.)
- EPS Estimate
- -0.19
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Modest Leverage
Modest leverage provides some financial cushioning while the company funds clinical development. Lower debt exposure can reduce near-term balance-sheet pressure and preserve flexibility for research spending, although this benefit remains limited by continuing losses and cash use.
Multi-indication Pipeline
Coverage of CNS, inflammatory, and cardiometabolic diseases gives the company several potential therapeutic avenues rather than dependence on one disease area. This breadth can support longer-term pipeline optionality if development programs produce differentiated clinical results.
Lead Program Focus
A defined lead program gives the clinical-stage business a central development focus and a clear basis for advancing toward potential product validation. Progress in schizophrenia and related indications could also provide a foundation for evaluating subsequent pipeline opportunities.
Bears Say
No Commercial Revenue
The absence of revenue means the company has not yet demonstrated commercial monetization of its pipeline. Persistent operating and net losses require continued investment before product economics can be proven, leaving results highly dependent on clinical and development progress.
Persistent Cash Burn
Sustained negative operating and free cash flow indicates that operations continue to consume capital rather than generate funding internally. The much larger TTM outflow increases the likelihood of ongoing external funding needs and makes financial planning less predictable.
Volatile Reported Balance Sheet
Sharp changes in reported equity and assets make the balance-sheet trajectory harder to assess and reduce confidence in the stability of the reported capital base. Combined with ongoing losses, this volatility can complicate financing and longer-term capital allocation decisions.
Reviva Pharmaceuticals Holdings News
OTC Market Listing Exposes Reviva Pharmaceuticals to Volatility, Illiquidity and Pricing Risks
Reviva Pharmaceuticals Holdings, Inc. (RVPH) has disclosed a new risk, in the Capital Markets category. The analyst notes that reliance on the OTC Markets exposes Reviva Pharmaceuticals Holdings, Inc. to
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
What is Reviva Pharmaceuticals Holdings’s market cap?
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Is Reviva Pharmaceuticals Holdings overvalued?
Does Reviva Pharmaceuticals Holdings pay dividends?
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laxminarayan Bhat
- Employees
- 14
- Website
- www.revivapharma.com
- Address
- 10080 N. Wolfe Road, Cupertino, CA, 95014, US
Reviva Pharmaceuticals Holdings (RVPH) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |














